These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 24560023)

  • 21. Biosimilar Treatments Have Practice Implications.
    Wiley K
    ONS Connect; 2016 Apr; 31(4):38. PubMed ID: 27209660
    [No Abstract]   [Full Text] [Related]  

  • 22. Looking to the future and learning lessons from the recent past: changing stakeholder perceptions of biosimilars in cancer.
    Kim WS; Ogura M; Kwon HC; Choi D
    Future Oncol; 2017 May; 13(15s):17-29. PubMed ID: 28482701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Biosimilar drugs in oncology].
    Levêque D
    Bull Cancer; 2016 Mar; 103(3):294-8. PubMed ID: 26832422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of biosimilar medicines in oncology - position statement of the Brazilian Society of Clinical Oncology (SBOC).
    Fernandes GS; Sternberg C; Lopes G; Chammas R; Gifoni MAC; Gil RA; Araujo DV
    Braz J Med Biol Res; 2018 Jan; 51(3):e7214. PubMed ID: 29340530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A clinician's guide to biosimilars in oncology.
    Rugo HS; Linton KM; Cervi P; Rosenberg JA; Jacobs I
    Cancer Treat Rev; 2016 May; 46():73-9. PubMed ID: 27135548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biosimilars in an era of rising oncology treatment options.
    Peeters M; Planchard D; Pegram M; Gonçalves J; Bocquet F; Jang H
    Future Oncol; 2021 Oct; 17(29):3881-3892. PubMed ID: 34189937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Japanese regulatory authority's perspective on biosimilars.
    Nagai S; Yanagihara R; Kishioka Y
    Lancet Oncol; 2015 Mar; 16(3):e101. PubMed ID: 25752552
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacovigilance and biosimilars: considerations, needs and challenges.
    Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
    Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Japanese regulatory authority's perspective on biosimilars - authors' reply.
    Bennett CL; Chen B; Hermanson T; Georgantopoulos P; Sartor OA
    Lancet Oncol; 2015 Mar; 16(3):e102. PubMed ID: 25752553
    [No Abstract]   [Full Text] [Related]  

  • 30. From the editor-in-chief: new ways to pay for cures.
    Alvarnas J
    Am J Manag Care; 2019 Jun; 25(6 Spec No.):SP185. PubMed ID: 31233305
    [No Abstract]   [Full Text] [Related]  

  • 31. [New therapeutic strategies in oncology].
    Bohuon C
    Ann Pharm Fr; 2010 Jul; 68(4):203-4. PubMed ID: 20637352
    [No Abstract]   [Full Text] [Related]  

  • 32. Barriers to Oncology Biosimilars Uptake in the United States.
    Nabhan C; Valley A; Feinberg BA
    Oncologist; 2018 Nov; 23(11):1261-1265. PubMed ID: 30049886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Conversation with Gary Lyman, MD: Biosimilars and the Search for the Cure To Cancer Treatment's Financial Toxicity.
    Wehrwein P
    Manag Care; 2019 Jan; 28(1):12-15. PubMed ID: 30883317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biosimilar Impact on Oncology Clinical Trial Design and Operations.
    Chen J; Ngo D; Yi A
    JCO Oncol Pract; 2022 Mar; 18(3):157-160. PubMed ID: 34597161
    [No Abstract]   [Full Text] [Related]  

  • 35. American Society of Clinical Oncology Position Statement on Addressing the Affordability of Cancer Drugs.
    American Society of Clinical Oncology
    J Oncol Pract; 2018 Mar; 14(3):187-192. PubMed ID: 29091534
    [No Abstract]   [Full Text] [Related]  

  • 36. Biosimilars in oncology: key role of nurses in patient education.
    Waller CF; Friganović A
    Future Oncol; 2020 Sep; 16(25):1931-1939. PubMed ID: 32618476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utilizing oncology biosimilars to minimize the economic burden associated with cancer treatment: managed care considerations.
    Liu Y
    Am J Manag Care; 2021 Aug; 27(14 Suppl):. PubMed ID: 34403576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First US biosimilar launch.
    Nat Biotechnol; 2015 Oct; 33(10):1013. PubMed ID: 26448071
    [No Abstract]   [Full Text] [Related]  

  • 39. ESMO 2014: new trends in precision medicine.
    Morere JF; Innominato P
    Target Oncol; 2014 Dec; 9(4):293-4. PubMed ID: 25503266
    [No Abstract]   [Full Text] [Related]  

  • 40. [Biosimilars - Potential, risks and open questions].
    Dtsch Med Wochenschr; 2014 Jan; 139(1-2):12-3. PubMed ID: 24551883
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.